SHWB Medical is a medical technology company focusing on the field of neurointervention, and is committed to becoming the medical technology company that saves the most lives of stroke patients in the world. The company's headquarters and production base are located in Shanghai Medical Valley, with a R&D center in the United States. The company mainly develops and produces international high-end innovative products for the treatment of vascular diseases.
SHWB has a professional R&D team in the field of neurointervention. The U.S. R&D team and the Chinese technical team have worked together to develop many breakthrough neurointervention products. Now they have carried out R&D and clinical trials of many products, and have formed dozens of international and domestic products.
In 2018, SHWB became the first Chinese company to obtain FDA certification for neurointerventional therapy products, and officially entered the international market in early 2019. The products have been exported to more than 10 countries including the United States, Germany, the United Kingdom, and Chile.
"Cerebral Vascular Aneurysm Embolization Coil System" is the company's first neuroembolization interventional medical product certified by the US FDA, EU CE and Japan PMDA. It was officially marketed in the United States in the second half of 2019. It has now entered UCLA, Kaiser (Kaiser) Medical Group), Klinikum Stuttgart, BHRHospital and other internationally renowned hospitals. In terms of registration in China, the company cooperates with top hospitals such as Tiantan Hospital, Xuanwu Hospital and Huashan Hospital to carry out clinical trials in preparation for the rapid opening of the domestic market.
